JP2019521647A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521647A5
JP2019521647A5 JP2018556354A JP2018556354A JP2019521647A5 JP 2019521647 A5 JP2019521647 A5 JP 2019521647A5 JP 2018556354 A JP2018556354 A JP 2018556354A JP 2018556354 A JP2018556354 A JP 2018556354A JP 2019521647 A5 JP2019521647 A5 JP 2019521647A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
abgdf15
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018556354A
Other languages
English (en)
Japanese (ja)
Other versions
JP7138567B2 (ja
JP2019521647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/029636 external-priority patent/WO2017189724A1/en
Publication of JP2019521647A publication Critical patent/JP2019521647A/ja
Publication of JP2019521647A5 publication Critical patent/JP2019521647A5/ja
Application granted granted Critical
Publication of JP7138567B2 publication Critical patent/JP7138567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018556354A 2016-04-27 2017-04-26 成長分化因子15に対する抗体およびそれらの使用 Active JP7138567B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328564P 2016-04-27 2016-04-27
US62/328,564 2016-04-27
PCT/US2017/029636 WO2017189724A1 (en) 2016-04-27 2017-04-26 Antibodies against growth differentiation factor 15 and uses thereof

Publications (3)

Publication Number Publication Date
JP2019521647A JP2019521647A (ja) 2019-08-08
JP2019521647A5 true JP2019521647A5 (enExample) 2020-05-28
JP7138567B2 JP7138567B2 (ja) 2022-09-16

Family

ID=58672775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556354A Active JP7138567B2 (ja) 2016-04-27 2017-04-26 成長分化因子15に対する抗体およびそれらの使用

Country Status (5)

Country Link
US (1) US11312766B2 (enExample)
EP (1) EP3448887A1 (enExample)
JP (1) JP7138567B2 (enExample)
CN (1) CN109071647B (enExample)
WO (1) WO2017189724A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109709331B (zh) * 2019-01-29 2022-02-25 瑞博奥(广州)生物科技股份有限公司 Gdf15在制备用于定量检测肝癌标志物的试剂盒中的用途
WO2021111636A1 (ja) * 2019-12-06 2021-06-10 大塚製薬株式会社 抗gdf15抗体
CN114560938B (zh) * 2020-03-30 2023-05-23 中国人民解放军第四军医大学 抗gdf15中和性单克隆抗体及其应用
IL302646A (en) * 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
MX2023011655A (es) 2021-03-31 2023-10-11 Cambridge Entpr Ltd Inhibidores terapeuticos de la se?alizacion de gdf15.
IL310535A (en) * 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
CA3250445A1 (en) * 2022-01-26 2025-03-10 Yunnan Baiyao Group Co., Ltd. ANTIBODY MOLECULE DIRECTED AGAINST DIFFERENTIATION AND GROWTH FACTOR 15 AND ITS USE
CN119487065A (zh) * 2022-05-09 2025-02-18 舒泰神(北京)生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
CN120518762B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用
WO2025146488A1 (en) 2024-01-05 2025-07-10 Catalym Gmbh Anti-hgdf-15 antibody for use in the treatment of cancer in a patient in combination with a cancer antigen-targeted drug conjugate that induces cancer cell stress
CN119735675B (zh) * 2024-12-10 2025-05-27 北京开景基因技术有限公司 一种抗gdf15抗体及其制备方法和应用
CN119431583B (zh) * 2024-12-19 2025-09-30 重庆国际免疫创新中心有限公司 靶向cd155的抗体或抗原结合片段及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CA2196200A1 (en) 1994-07-29 1996-02-15 Michael Joseph Browne Novel compounds
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
SE9603936D0 (sv) 1996-10-25 1996-10-25 Sandvik Ab Method of making cemented carbide by metal injection molding
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
ATE282092T1 (de) 1997-06-11 2004-11-15 Borean Pharma As Trimerisierendes modul
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7498352B2 (en) * 2001-06-26 2009-03-03 Takeda Pharmaceutical Company Limited TGF-β superfamily production/secretion promoter
JP4344242B2 (ja) * 2001-09-18 2009-10-14 バイオエキスパータイズ, エルエルシー Igf結合タンパク質由来のペプチドまたは低分子
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP2990053A1 (en) 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
PT2441466E (pt) 2004-04-13 2014-09-09 St Vincents Hosp Sydney Agente de inibição de mic-1
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
CN102203619B (zh) * 2008-10-31 2015-12-16 圣文森特医院悉尼有限公司 慢性肾病中的预测方法
EA027071B1 (ru) * 2009-04-27 2017-06-30 Новартис Аг АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
CN104853775B (zh) * 2012-09-26 2023-10-20 尤利乌斯·马克西米利安维尔茨堡大学 针对生长和分化因子15(gdf-15)的单克隆抗体
MX370720B (es) * 2012-12-21 2019-12-20 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15.
BR122023027559A2 (pt) * 2014-03-26 2024-01-30 Julius-Maximilians-Universität Würzburg Anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15), estojo compreendendo os mesmos, vetor de expressão que codifica os mesmos e linhagem de célula capaz de produzir os mesmos
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
US20170137505A1 (en) 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
CA2952032C (en) 2014-06-20 2023-03-14 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
PL3197493T3 (pl) 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego

Similar Documents

Publication Publication Date Title
JP2019521647A5 (enExample)
JP7106234B2 (ja) 二重特異性抗体を製造する方法、二重特異性抗体及びこのような抗体の治療的使用
JP2018521691A5 (enExample)
JP2025179073A (ja) 二重特異性抗体
JP2020023523A5 (enExample)
JP2010526028A5 (enExample)
JP2019522961A5 (enExample)
JP2017535257A5 (enExample)
JP2013543384A5 (enExample)
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
JP2017500018A5 (enExample)
JP2015503909A5 (enExample)
JP2018510617A5 (enExample)
JP2014503482A5 (enExample)
JP2014509510A5 (enExample)
JP2019527543A5 (enExample)
JP2014519334A5 (enExample)
JP2013538553A5 (enExample)
JP2013519364A5 (enExample)
CN106565840B (zh) 抗乙肝表面抗原的抗体及其用途
HRP20210393T1 (hr) Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja
CA2699834A1 (en) Improved anti-il-6 receptor antibody
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2011528902A5 (enExample)
JP2012524524A5 (enExample)